Clinical Evaluation of the Results of Treatment of Severe Coronavirus Disease (COVID-19) Caused by SARS-COV-2 in Patients with Pneumonia and Pneumo-Pleurofibrosis Using Modern Pharmacotherapy to Protect Public Health

The COVID-19 pandemic prompted the development of innovative approaches to the treatment of severe forms of pneumonia with pneumo-pleurofibrosis. An IV regimen based on intravenous administration of ethyl alcohol solutions of different concentrations with glucose in patients with COVID-19 (intervention group and control groups of comparable number) was proposed and clinically evaluated. The use of 10% Ethanol has been introduced: 150 ml intravenously drip 2 times a day for 7 days. In both groups, hyperthermia, tachypnea, dry cough, pleural pain, diffuse cyanosis, severe general condition, a significant decrease in oxygen saturation, leukocytosis and lymphopenia were found at the beginning of treatment. In the intervention group, the normalization of indicators occurred much faster: body temperature returned to normal on the fifth to seventh day versus the twelfth-fourteenth in the control; respiratory rate – on the fourth to fifth day versus the sixteenth to eighteenth; saturation reached normal on the sixth to eighth day against the twelfth-fifteenth; leukocytes returned to normal on the tenth to eleventh day against the sixteenth to eighteenth; Lymphocytes stabilized on the sixth to eighth day versus the twentieth to twenty-second. On the seventh day, a satisfactory condition was observed in most patients in the intervention group without deaths, in the control - much later and in smaller numbers. The technique of using intravenous ethanol is based on the classical principles of detoxification therapy: elimination of the toxic factor with subsequent elimination of the consequences of intoxication, which provides an etiotropic-pathogenetic effect in acute vasculitis and pneumo-pleurofibrosis. The proposed scheme reduces the duration of treatment, reduces costs, and requires further clinical, pharmacological and pharmacoeconomic studies.